For how we live.
SWITCH-SWEDEHEART randomised regions rather than patients. Over 17,095 people, a default prasugrel policy did not lower ischaemic events against ticagrelor, but major bleeding was lower.
PREMIUM tested prasugrel alone against aspirin plus prasugrel in 2,216 STEMI patients in Japan. Monotherapy failed to show noninferiority, and the confidence interval sat above one.
A first consolidated audit of PBS and PHARMAC cardiovascular listings from 2023 to 2025 finds a widening access gap between two neighbouring countries with similar disease burdens.